I’ve been watching this stock for awhile. It was the “darling” stock before the market crash in Feb and it dropped a whole lot from its ATH. 

I think it shows some promise in terms of market reach due to changing its model to a “rental” model so most labs don’t need to outright buy the Saphry system. However, I’ve read that most hospitals and bigger reasearch labs are unlikely to adopt it since it has far less use cases than Pacific Biosciences gene sequencing system.

Keeping my fingers crossed it will see more uptake going forward